<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35723868</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-6901</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Drugs in R&amp;D</Title><ISOAbbreviation>Drugs R D</ISOAbbreviation></Journal><ArticleTitle>Analysis of the US Safety Data for Edaravone (Radicava<sup>&#xae;</sup>) From the Third Year After Launch.</ArticleTitle><Pagination><StartPage>205</StartPage><EndPage>211</EndPage><MedlinePgn>205-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40268-022-00391-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease with no curative therapies. Edaravone (Radicava<sup>&#xae;</sup>) (Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan), approved in the United States (US) for ALS in adults in 2017, was shown in a clinical trial to slow the rate of physical functional decline in ALS and is administered intravenously. The aim of this paper is to summarize the observed safety profile from real-world patient use during the first 3&#xa0;years of edaravone availability in the US.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Edaravone usage data were collected, and adverse events (AEs) were identified from a postmarketing safety database from August 8, 2017 through August 7, 2020 (cutoff date).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As of October 3, 2020, 5207 ALS patients had been treated with edaravone. As of August 7, 2020, the most commonly reported AEs included death (not specified), drug ineffective, disease progression, therapeutic response unexpected, fall, asthenia, fatigue, muscular weakness, gait disturbance, and dyspnea. The most commonly reported serious AEs (SAEs) included death (not specified), pneumonia, disease progression, ALS, fall, dyspnea, respiratory failure, device-related infection, hospitalization, and injection-site infection. There were 687 deaths, with 494 reported as death without specifying the cause. Deaths were most commonly attributed to ALS, disease progression, respiratory failure, or pneumonia. Review for administration-site reactions revealed 95 AEs, including 34 site infections, with 22 SAEs (all non-fatal). Five non-fatal SAEs of anaphylaxis were reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In the postmarketing reporting to date, no new safety signals were identified beyond those already known from the edaravone clinical trial program.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Genge</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Benjamin Rix</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine-Charlotte Campus, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalin</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3051-3953</Identifier><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ, USA. stephen_apple@mt-pharma-us.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bower</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma Development America, Inc., Jersey City, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs R D</MedlineTA><NlmUniqueID>100883647</NlmUniqueID><ISSNLinking>1174-5886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="Y">Edaravone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>AG, BRB, and BO are consultants for MTPA. BW, AK, MJ, and LB are employees of Mitsubishi Tanabe Pharma Development America, Inc. SA is an employee of Mitsubishi Tanabe Pharma America, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35723868</ArticleId><ArticleId IdType="pmc">PMC9433633</ArticleId><ArticleId IdType="doi">10.1007/s40268-022-00391-6</ArticleId><ArticleId IdType="pii">10.1007/s40268-022-00391-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy&#x2014;a roundtable discussion. Am J Manag Care. 2018;24(9 suppl):S175&#x2013;S186.</Citation><ArticleIdList><ArticleId IdType="pubmed">29693363</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010&#x2013;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5&#x2013;6):413&#x2013;420. doi: 10.1080/21678421.2019.1612435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1612435</ArticleId><ArticleId IdType="pmc">PMC6946020</ArticleId><ArticleId IdType="pubmed">31131638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Radicava&#xae; (edaravone injection) [package insert]. Jersey City: Mitsubishi Tanabe Pharma Corporation; August 2018.</Citation></Reference><Reference><Citation>Rilutek&#xae; (riluzole) [package insert]. Bridgewater: Sanofi-aventis U.S. LLC; November 2012.</Citation></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C, Heiman-Patterson T, Kittrell P, Baranovsky T, McAnanama G, Bower L, et al. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):605&#x2013;610. doi: 10.1080/21678421.2019.1645858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1645858</ArticleId><ArticleId IdType="pubmed">31364409</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood RA, Camargo CA, Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461&#x2013;467. doi: 10.1016/j.jaci.2013.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2013.08.016</ArticleId><ArticleId IdType="pubmed">24144575</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole DE. Sulfites and parenteral nutrition. CMAJ. 1986;134(1):17&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1490599</ArticleId><ArticleId IdType="pubmed">3079658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavoie JC, Chessex P. Biologic effects of parenteral bisulfite on human vascular tissue. Pediatr Res. 1993;33(4 Pt 1):347&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnison AF, Jacobsen DW. Sulfite hypersensitivity. A critical review. CRC Crit Rev Toxicol. 1987;17(3):185&#x2013;214. doi: 10.3109/10408448709071208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10408448709071208</ArticleId><ArticleId IdType="pubmed">3556020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. J Allergy Clin Immunol Pract. 2014;2(2):168&#x2013;171. doi: 10.1016/j.jaip.2013.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2013.10.002</ArticleId><ArticleId IdType="pubmed">24607044</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalin A, Medina-Paraiso E, Ishizaki K, Kim A, Zhang Y, Saita T, et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(suppl 1):71&#x2013;79. doi: 10.1080/21678421.2017.1362440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1362440</ArticleId><ArticleId IdType="pubmed">28872919</ArticleId></ArticleIdList></Reference><Reference><Citation>Anibarro B, Caballero T, Garcia-Ara C, Diaz-Pena JM, Ojeda JA. Asthma with sulfite intolerance in children: a blocking study with cyanocobalamin. J Allergy Clin Immunol. 1992;90(1):103&#x2013;109. doi: 10.1016/S0091-6749(06)80016-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-6749(06)80016-3</ArticleId><ArticleId IdType="pubmed">1629495</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean RK, Subedi R, Christiano P, Ghimire A. More than a drink: a rare anaphylactic reaction to sparkling water. Am J Emerg Med. 2018;36(1):170 e1&#x2013;e2. doi: 10.1016/j.ajem.2017.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2017.10.019</ArticleId><ArticleId IdType="pubmed">29031480</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto N, Bito T, Hiura N, Yamamoto A, Iida M, Baba Y, et al. Food additives (hypochlorous acid water, sodium metabisulfite, and sodium sulfite) strongly affect the chemical and biological properties of vitamin B12 in aqueous solution. ACS Omega. 2020;5(11):6207&#x2013;6214. doi: 10.1021/acsomega.0c00425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.0c00425</ArticleId><ArticleId IdType="pmc">PMC7097994</ArticleId><ArticleId IdType="pubmed">32226906</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81(14):1222&#x2013;1225. doi: 10.1212/WNL.0b013e3182a6cc13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: what is protecting whom? Front Neurol. 2016;7:47. doi: 10.3389/fneur.2016.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00047</ArticleId><ArticleId IdType="pmc">PMC4810157</ArticleId><ArticleId IdType="pubmed">27065942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodar EJ, Simon A, de Visser M, van der Meer JW. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra) Neth J Med. 2009;67(9):302&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">19841487</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehme D, Paal G, Kersten W, Kersten H. Skin reaction in children and adults with central nervous system disease after intracutaneous administration of myelin preparations derived from human brain. Nature. 1963;199:84&#x2013;85. doi: 10.1038/199084a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/199084a0</ArticleId><ArticleId IdType="pubmed">14054526</ArticleId></ArticleIdList></Reference><Reference><Citation>Behan PO, Bakheit AM. Association of amyotrophic lateral sclerosis, Hoigne's syndrome and residence in Guam. J Neurol Neurosurg Psychiatry. 1991;54(1):90&#x2013;91. doi: 10.1136/jnnp.54.1.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.54.1.90</ArticleId><ArticleId IdType="pmc">PMC1014312</ArticleId><ArticleId IdType="pubmed">2010769</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon-Siatoya WT, Carrillo-Martin I, Rodenas M, Gonzalez-Estrada A. IgE-mediated reaction to levamisole: evaluation of a patient with severe anaphylaxis. Cureus. 2021;13(9):e17815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500243</ArticleId><ArticleId IdType="pubmed">34660025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(11):1083&#x2013;1091. doi: 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires SS, Rebeiro PF, Miller M, Koss K, Wright PW, Talbot TR. Medically attended catheter complications are common in patients with outpatient central venous catheters. Infect Control Hosp Epidemiol. 2018;39(4):439&#x2013;444. doi: 10.1017/ice.2018.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2018.8</ArticleId><ArticleId IdType="pmc">PMC5972823</ArticleId><ArticleId IdType="pubmed">29444733</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller SC, Williams D, Gavgani M, Hirsch D, Adamovich J, Hohl D, et al. Environmental exposures and the risk of central venous catheter complications and readmissions in home infusion therapy patients. Infect Control Hosp Epidemiol. 2017;38(1):68&#x2013;75. doi: 10.1017/ice.2016.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2016.223</ArticleId><ArticleId IdType="pmc">PMC5502130</ArticleId><ArticleId IdType="pubmed">27697084</ArticleId></ArticleIdList></Reference><Reference><Citation>Paras-Bravo P, Paz-Zulueta M, Sarabia-Lavin R, Jose Amo-Setien F, Herrero-Montes M, Olavarria-Beivide E, et al. Complications of peripherally inserted central venous catheters: a retrospective cohort study. PLoS&#xa0;One. 2016;11(9):e0162479. doi: 10.1371/journal.pone.0162479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162479</ArticleId><ArticleId IdType="pmc">PMC5010186</ArticleId><ArticleId IdType="pubmed">27588946</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen LD, Holst M, Bech LF, Drustrup L, Nygaard L, Skallerup A, et al. Comparison of complications associated with peripherally inserted central catheters and Hickman catheters in patients with intestinal failure receiving home parenteral nutrition. Six-year follow up study. Clin Nutr. 2016;35(4):912&#x2013;917. doi: 10.1016/j.clnu.2015.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2015.06.009</ArticleId><ArticleId IdType="pubmed">26269383</ArticleId></ArticleIdList></Reference><Reference><Citation>Saqui O, Fernandes G, Allard J. Central venous catheter infection in Canadian home parenteral nutrition patients: a 5-year multicenter retrospective study. Br J Nurs. 2020;29(8):S34&#x2013;S42. doi: 10.12968/bjon.2020.29.8.S34.</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/bjon.2020.29.8.S34</ArticleId><ArticleId IdType="pubmed">32324464</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Is edaravone harmful? (A placebo is not a control) Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):477&#x2013;482. doi: 10.1080/21678421.2018.1517179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1517179</ArticleId><ArticleId IdType="pubmed">30373406</ArticleId></ArticleIdList></Reference><Reference><Citation>Genge A, Brooks B. Edaravone administration in pivotal clinical Study 19. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):298&#x2013;299. doi: 10.1080/21678421.2019.1582672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582672</ArticleId><ArticleId IdType="pubmed">31079469</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin) Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):300&#x2013;302. doi: 10.1080/21678421.2019.1582675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582675</ArticleId><ArticleId IdType="pubmed">31074645</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Reappraisal of an ALS trial: unaccounted procedural risk. Lancet Neurol. 2020;19(9):717&#x2013;718. doi: 10.1016/S1474-4422(20)30265-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30265-9</ArticleId><ArticleId IdType="pubmed">32822626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit R, Truffinet P, et al. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(1):23&#x2013;29. doi: 10.1080/146608202317576507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608202317576507</ArticleId><ArticleId IdType="pubmed">12061945</ArticleId></ArticleIdList></Reference><Reference><Citation>Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(3):153&#x2013;158. doi: 10.1080/146608201753275508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608201753275508</ArticleId><ArticleId IdType="pubmed">11771772</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, et al. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve. 2018;57(1):20&#x2013;24. doi: 10.1002/mus.25712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25712</ArticleId><ArticleId IdType="pubmed">28561886</ArticleId></ArticleIdList></Reference><Reference><Citation>Santangelo G, Siciliano M, Trojano L, Femiano C, Monsurro MR, Tedeschi G, et al. Apathy in amyotrophic lateral sclerosis: insights from Dimensional Apathy Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5&#x2013;6):434&#x2013;442. doi: 10.1080/21678421.2017.1313865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1313865</ArticleId><ArticleId IdType="pubmed">28431489</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JM, Kim SY, Park D, Park JS. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Neurol Sci. 2020;41(1):119&#x2013;123. doi: 10.1007/s10072-019-04055-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04055-3</ArticleId><ArticleId IdType="pmc">PMC7223963</ArticleId><ArticleId IdType="pubmed">31471712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, Caponnetto C, Dubbioso R, Giannini F, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258&#x2013;3267. doi: 10.1007/s00415-020-09993-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):260&#x2013;263. doi: 10.1080/21678421.2019.1572191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572191</ArticleId><ArticleId IdType="pubmed">30784320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz JF, Khan SA, Salem A, Lin Z, Iqbal Z, Jahan N. Post-marketing experience of edaravone in amyotrophic lateral sclerosis: a clinical perspective and comparison with the clinical trials of the drug. Cureus. 2020;12(10):e10818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645306</ArticleId><ArticleId IdType="pubmed">33173626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura K, Ishizaki K, Yoshida K, Matsuda M, Kawaguchi Y, Yuki S, et al. Safety information of patients from ongoing post-marketing surveillance, evaluating the real-world efficacy and safety of edaravone for amyotrophic lateral sclerosis patients in Japan (SUNRISE Japan) (CMS-35). Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(suppl 2).</Citation></Reference><Reference><Citation>Berry J, Brooks B, Genge A, Heiman-Patterson T, Appel S, Benatar M, et al. Protocol and design of the Radicava&#xae; (edaravone) biomarker study for ALS patients in the United States (CLT-40) Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(suppl 1):286&#x2013;287.</Citation></Reference><Reference><Citation>Shimizu H, Nishimura Y, Shiide Y, Matsuda H, Akimoto M, Matsuda M, et al. Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10(10):1174&#x2013;1187. doi: 10.1002/cpdd.925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.925</ArticleId><ArticleId IdType="pmc">PMC8518673</ArticleId><ArticleId IdType="pubmed">33704925</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nishimura Y, Shiide Y, Yoshida K, Hirai M, Matsuda M, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188&#x2013;1197. doi: 10.1002/cpdd.952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.952</ArticleId><ArticleId IdType="pmc">PMC8518908</ArticleId><ArticleId IdType="pubmed">33955162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>